Stay updated on Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedAdded Contacts/Locations and Study Status sections to the study record history, reflecting updated recruitment status and site information.SummaryDifference0.2%

- Check10 days agoChange DetectedRevision: v3.3.3 was added to the Record History and the items HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the footer.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedA new revision entry v3.3.2 has been added to the page history, replacing the previous v3.2.0; there are no user-impact changes to page content or study data detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check38 days agoChange DetectedRemoved a site-wide government funding and operating status notice. This change does not affect trial data or study records; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check61 days agoChange DetectedNew history entries were added showing updated submission dates and study status, expanding the chronological record of the trial.SummaryDifference0.0%

- Check68 days agoChange DetectedAdded current date (2025-10-20) and a new Study Status entry (2025-10-10); removed an older date (2025-08-07). This updates time-sensitive content and study status to reflect new information.SummaryDifference0.8%

Stay in the know with updates to Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.